Cytokines and their receptors as biomarkers of systemic lupus erythematosus

Expert Review of Molecular Diagnostics

Volumn 8, Issue 2, 2008, Pages 189-198

  Suh, Chang Hee ^a   Kim, Hyoun Ah ^a  

^a Ajou University School of Medicine   (South Korea)

Author keywords

Biomarker; Cytokine; Cytokine receptor; Disease activity; Erythematosus; Systemic lupus

Indexed keywords

ALPHA INTERFERON; BIOLOGICAL MARKER; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 16; INTERLEUKIN 18; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 4; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

B LYMPHOCYTE; BLOOD LEVEL; CLINICAL EVALUATION; CLINICAL FEATURE; DISEASE ACTIVITY; HUMAN; IMMUNE DYSREGULATION; REVIEW; STATISTICAL SIGNIFICANCE; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE;

ANIMALS; BIOLOGICAL MARKERS; CYTOKINES; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MONITORING, PHYSIOLOGIC; PROGNOSIS; RECEPTORS, CYTOKINE;

EID: 41549109044     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/14737159.8.2.189     Document Type: Review

References (82)

1. D'Cruz DP, Khamashta MA, Hughes GR. Systemic lupus erythematosus. Lancet 369, 587-596 (2007).
2. Kyttaris VC, Krishnan S, Tsokos GC. Systems biology in systemic lupus erythematosus: integrating genes, biology and immune function. Autoimmunity 39, 705-709 (2006).
3. Uramoto KM, Michet CJ Jr, Thumboo J, Sunku J, O'Fallon WM, Gabriel SE. Trends in the incidence and mortality of systemic lupus erythematosus, 1950-1992. Arthritis Rheum. 42, 46-50 (1999).
4. Bernatsky S, Boivin JF, Joseph L et al. Mortality in systemic lupus erythematosus. Arthritis Rheum. 54, 2550-2557 (2006).
5. Cervera R, Khamashta MA, Font J et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore) 82, 299-308 (2003).
6. Merrill JT, Buyon JP. The role of biomarkers in the assessment of lupus. Best Pract. Res. Clin. Rheumatol. 19, 709-726 (2005).
7. Liu CC, Manzi S, Ahearn JM. Biomarkers for systemic lupus erythematosus: a review and perspective. Curr. Opin. Rheumatol. 17, 543-549 (2005).
8. Schiffenbauer J, Hahn B, Weisman MH, Simon LS. Biomarkers, surrogate markers, and design of clinical trials of new therapies for systemic lupus erythematosus. Arthritis Rheum. 50, 2415-2422 (2004).
9. Mittleman BB. Biomarkers for systemic lupus erythematosus: has the right time finally arrived? Arthritis Res. Ther. 6, 223-224 (2004).
10. Illei GG, Tackey E, Lapteva L, Lipsky PE. Biomarkers in systemic lupus erythematosus: II. Markers of disease activity. Arthritis Rheum. 50, 2048-2065 (2004).
11. Illei GG, Tackey E, Lapteva L, Lipsky PE. Biomarkers in systemic lupus erythematosus. I. General overview of biomarkers and their applicability. Arthritis Rheum. 50, 1709-1720 (2004).
12. Kirou KA, Salmon JE, Crow MK. Soluble mediators as therapeutic targets in systemic lupus erythematosus: cytokines, immunoglobulin receptors, and the complement system. Rheum. Dis. Clin. North Am. 32, 103-119, ix (2006).
13. Doria A, Ghirardello A, Iaccarino L et al. Pregnancy, cytokines, and disease activity in systemic lupus erythematosus. Arthritis Rheum. 51, 989-995 (2004).
14. Lit LC, Wong CK, Li EK, Tam LS, Lam CW, Lo YM. Elevated gene expression of Th1/Th2 associated transcription factors is correlated with disease activity in patients with systemic lupus erythematosus. J. Rheumatol. 34, 89-96 (2007).
15. Gomez D, Correa PA, Gomez LM, Cadena J, Molina JF, Anaya JM. Th1/Th2 cytokines in patients with systemic lupus erythematosus: is tumor necrosis factor α protective? Semin. Arthritis Rheum. 33, 404-413 (2004).
16. Gladman DD. Systemic lupus erythematosus disease activity index 2000. J. Rheumatol. 29, 288-291 (2002).
17. Kallenberg CG, Stegeman CA, Bootsma H, Bijl M, Limburg PC. Quantitation of autoantibodies in systemic autoimmune diseases: clinically useful? Lupus 15, 397-402 (2006).
18. Manzi S, Ahearn JM, Salmon J. New insights into complement: a mediator of injury and marker of disease activity in systemic lupus erythematosus. Lupus 13, 298-303 (2004).
19. Dellalibera-Joviliano R, Dos Reis ML, Cunha Fde Q, Donadi EA. Kinins and cytokines in plasma and cerebrospinal fluid of patients with neuropsychiatric lupus. J. Rheumatol. 30, 485-492 (2003).
20. Wais T, Fierz W, Stoll T, Villiger PM. Subclinical disease activity in systemic lupus erythematosus: immunoinflammatory markers do not normalize in clinical remission. J. Rheumatol. 30, 2133-2139 (2003).
21. Capper ER, Maskill JK, Gordon C, Blakemore AI. Interleukin (IL)-10, IL-1ra and IL-12 profiles in active and quiescent systemic lupus erythematosus: could longitudinal studies reveal patient subgroups of differing pathology? Clin. Exp. Immunol. 138, 348-356 (2004).
22. Nelson BH. IL-2, regulatory T cells, and tolerance. J. Immunol. 172, 3983-3988 (2004).
23. Chan RW, Lai FM, Li EK et al. Intrarenal cytokine gene expression in lupus nephritis. Ann. Rheum. Dis. 66, 886-892 (2007).
24. Lit LC, Wong CK, Tam LS, Li EK, Lam CW. Raised plasma concentration and ex vivo production of inflammatory chemokines in patients with systemic lupus erythematosus. Ann. Rheum. Dis. 65, 209-215 (2006).
25. Chun HY, Chung JW, Kim HA et al. Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus. J. Clin. Immunol. 27, 461-466 (2007).
26. Daza L, Lavalle C, Duarte C, Huerta R, Moreno J. Lack of association between hyperprolactinemia and soluble IL-2 receptor levels in systemic lupus erythematosus. Lupus 12, 107-111 (2003).
27. Singh RR. IL-4 and many roads to lupuslike autoimmunity. Clin. Immunol. 108, 73-79 (2003).
28. Soltesz P, Aleksza M, Antal-Szalmas P, Lakos G, Szegedi G, Kiss E. Plasmapheresis modulates Th1/Th2 imbalance in patients with systemic lupus erythematosus according to measurement of intracytoplasmic cytokines. Autoimmunity 35, 51-56 (2002).
29. Kishimoto T. Interleukin-6: from basic science to medicine - 40 years in immunology. Annu. Rev. Immunol. 23, 1-21 (2005).
30. Tackey E, Lipsky PE, Illei GG. Rationale for interleukin-6 blockade in systemic lupus erythematosus. Lupus 13, 339-343 (2004).
31. Pramanik R, Jorgensen TN, Xin H, Kotzin BL, Choubey D. Interleukin-6 induces expression of Ifi202, an interferon-inducible candidate gene for lupus susceptibility. J. Biol. Chem. 279, 16121-16127 (2004).
32. Sabry A, Sheashaa H, El-Husseini A et al. Proinflammatory cytokines (TNF-α and IL-6) in Egyptian patients with SLE: its correlation with disease activity. Cytokine 35, 148-153 (2006).
33. Wozniacka A, Lesiak A, Narbutt J, McCauliffe DP, Sysa-Jedrzejowska A. Chloroquine treatment influences proinflammatory cytokine levels in systemic lupus erythematosus patients. Lupus 15, 268-275 (2006).
34. Asanuma Y, Chung CP, Oeser A et al. Increased concentration of proatherogenic inflammatory cytokines in systemic lupus erythematosus: relationship to cardiovascular risk factors. J. Rheumatol. 33, 539-545 (2006).
35. Suh CH, Chun HY, Ye YM, Park HS. Unresponsiveness of C-reactive protein in the non-infectious inflammation of systemic lupus erythematosus is associated with interleukin 6. Clin. Immunol. 119, 291-296 (2006).
36. Ripley BJ, Goncalves B, Isenberg DA, Latchman DS, Rahman A. Raised levels of interleukin 6 in systemic lupus erythematosus correlate with anaemia. Ann. Rheum. Dis. 64, 849-853 (2005).
37. Sabry A, Elbasyouni SR, Sheashaa HA et al. Correlation between levels of TNF-α and IL-6 and hematological involvement in SLE Egyptian patients with lupus nephritis. Int. Urol. Nephrol. 38, 731-737 (2006).
38. Katsumata Y, Harigai M, Kawaguchi Y et al. Diagnostic reliability of cerebral spinal fluid tests for acute confusional state (delirium) in patients with systemic lupus erythematosus: interleukin 6 (IL-6), IL-8, interferon-α, IgG index, and Q-albumin. J. Rheumatol. 34, 2010-2017 (2007).
39. Pestka S, Krause CD, Sarkar D, Walter MR, Shi Y, Fisher PB. Interleukin-10 and related cytokines and receptors. Annu. Rev. Immunol. 22, 929-979 (2004).
40. Fickenscher H, Hor S, Kupers H, Knappe A, Wittmann S, Sticht H. The interleukin-10 family of cytokines. Trends Immunol. 23, 89-96 (2002).
41. Llorente L, Richaud-Patin Y. The role of interleukin-10 in systemic lupus erythematosus. J. Autoimmun. 20, 287-289 (2003).
42. Beebe AM, Cua DJ, de Waal Malefyt R. The role of interleukin-10 in autoimmune disease: systemic lupus erythematosus (SLE) and multiple sclerosis (MS). Cytokine Growth Factor Rev. 13, 403-412 (2002).
43. Enghard P, Langnickel D, Riemekasten G. T cell cytokine imbalance towards production of IFN-γ and IL-10 in NZB/W F1 lupus-prone mice is associated with autoantibody levels and nephritis. Scand. J. Rheumatol. 35, 209-216 (2006).
44. Grondal G, Traustadottir KH, Kristjansdottir H et al. Increased T-lymphocyte apoptosis/necrosis and IL-10 producing cells in patients and their spouses in Icelandic systemic lupus erythematosus multicase families. Lupus 11, 435-442 (2002).
45. Ronnelid J, Tejde A, Mathsson L, Nilsson-Ekdahl K, Nilsson B. Immune complexes from SLE sera induce IL10 production from normal peripheral blood mononuclear cells by an FcγRII dependent mechanism: implications for a possible vicious cycle maintaining B cell hyperactivity in SLE. Ann. Rheum. Dis. 62, 37-42 (2003).
46. Baraczka K, Nekam K, Pozsonyi T, Szuts I, Ormos G. Investigation of cytokine (tumor necrosis factor-α, interleukin-6, interleukin-10) concentrations in the cerebrospinal fluid of female patients with multiple sclerosis and systemic lupus erythematosus. Eur. J. Neurol. 11, 37-42 (2004).
47. Yin Z, Bahtiyar G, Zhang N et al. IL-10 regulates murine lupus. J. Immunol. 169, 2148-2155 (2002).
48. Tejde A, Mathsson L, Ekdahl KN, Nilsson B, Ronnelid J. Immune complex-stimulated production of interleukin-12 in peripheral blood mononuclear cells is regulated by the complement system. Clin. Exp. Immunol. 137, 521-528 (2004).
49. Lauwerys BR, Van Snick J, Houssiau FA. Serum IL-12 in systemic lupus erythematosus: absence of p70 heterodimers but presence of p40 monomers correlating with disease activity. Lupus 11, 384-387 (2002).
50. Tso TK, Huang WN, Huang HY, Chang CK. Elevation of plasma interleukin-18 concentration is associated with insulin levels in patients with systemic lupus erythematosus. Lupus 15, 207-212 (2006).
51. Spadaro A, Scrivo R, Bombardieri M et al. Relationship of interleukin-12 and interleukin-13 imbalance with class-specific rheumatoid factors and anticardiolipin antibodies in systemic lupus erythematosus. Clin. Rheumatol. 22, 107-111 (2003).
52. Mosaad YM, Metwally SS, Auf FA et al. Proinflammatory cytokines (IL-12 and IL-18) in immune rheumatic diseases: relation with disease activity and autoantibodies production. Egypt. J. Immunol. 10, 19-26 (2003).
53. Robak E, Robak T, Wozniacka A, Zak-Prelich M, Sysa-Jedrzejowska A, Stepien H. Proinflammatory interferon-γ - inducing monokines (interleukin-12, interleukin-18, interleukin-15) - serum profile in patients with systemic lupus erythematosus. Eur. Cytokine Netw. 13, 364-368 (2002).
54. Baranda L, de la Fuente H, Layseca-Espinosa E et al. IL-15 and IL-15R in leucocytes from patients with systemic lupus erythematosus. Rheumatology (Oxford) 44, 1507-1513 (2005).
55. Glass WG, Sarisky RT, Vecchio AM. Not-so-sweet sixteen: the role of IL-16 in infectious and immune-mediated inflammatory diseases. J. Interferon Cytokine Res. 26, 511-520 (2006).
56. Lard LR, Roep BO, Verburgh CA, Zwinderman AH, Huizinga TW. Elevated IL-16 levels in patients with systemic lupus erythematosus are associated with disease severity but not with genetic susceptibility to lupus. Lupus 11, 181-185 (2002).
57. Calvani N, Tucci M, Richards HB, Tartaglia P, Silvestris F. Th1 cytokines in the pathogenesis of lupus nephritis: the role of IL-18. Autoimmun. Rev. 4, 542-548 (2005).
58. Bossu P, Neumann D, Del Giudice E et al. IL-18 cDNA vaccination protects mice from spontaneous lupus-like autoimmune disease. Proc. Natl Acad. Sci. USA 100, 14181-14186 (2003).
59. Tso TK, Huang WN, Huang HY, Chang CK. Relationship of plasma interleukin-18 concentrations to traditional and non-traditional cardiovascular risk factors in patients with systemic lupus erythematosus. Rheumatology (Oxford) 45, 1148-1153 (2006).
60. Park MC, Park YB, Lee SK. Elevated interleukin-18 levels correlated with disease activity in systemic lupus erythematosus. Clin. Rheumatol. 23, 225-229 (2004).
61. Wong CK, Ho CY, Li EK, Tam LS, Lam CW. Elevated production of interleukin-18 is associated with renal disease in patients with systemic lupus erythematosus. Clin. Exp. Immunol. 130, 345-351 (2002).
62. Amerio P, Frezzolini A, Abeni D et al. Increased IL-18 in patients with systemic lupus erythematosus: relations with Th-1, Th-2, pro-inflammatory cytokines and disease activity. IL-18 is a marker of disease activity but does not correlate with pro-inflammatory cytokines. Clin. Exp. Rheumatol. 20, 535-538 (2002).
63. Sullivan KE, Suriano A, Dietzmann K, Lin J, Goldman D, Petri MA. The TNFα locus is altered in monocytes from patients with systemic lupus erythematosus. Clin. Immunol. 123, 74-81 (2007).
64. Aringer M, Graninger WB, Steiner G, Smolen JS. Safety and efficacy of tumor necrosis factor á blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum. 50, 3161-3169 (2004).
65. Aringer M, Feierl E, Steiner G et al. Increased bioactive TNF in human systemic lupus erythematosus: associations with cell death. Lupus 11, 102-108 (2002).
66. Sjowall C, Ernerudh J, Bengtsson AA, Sturfelt G, Skogh T. Reduced anti-TNFα autoantibody levels coincide with flare in systemic lupus erythematosus. J. Autoimmun. 22, 315-323 (2004).
67. Kyttaris VC, Juang YT, Tsokos GC. Immune cells and cytokines in systemic lupus erythematosus: an update. Curr. Opin. Rheumatol. 17, 518-522 (2005).
68. Mahmoud RA, El-Gendi HI, Ahmed HH. Serum neopterin, tumor necrosis factor-α and soluble tumor necrosis factor receptor II (p75) levels and disease activity in Egyptian female patients with systemic lupus erythematosus. Clin. Biochem. 38, 134-141 (2005).
69. Al-Mutairi S, Al-Awadhi A, Raghupathy R et al. Lupus patients with pulmonary involvement have a pro-inflammatory cytokines profile. Rheumatol. Int. 27, 621-630 (2007).
70. Aringer M, Smolen JS. Cytokine expression in lupus kidneys. Lupus 14, 13-18 (2005).
71. Crow MK, Kirou KA. Interferon-á in systemic lupus erythematosus. Curr. Opin. Rheumatol. 16, 541-547 (2004).
72. Baechler EC, Gregersen PK, Behrens TW. The emerging role of interferon in human systemic lupus erythematosus. Curr. Opin. Immunol. 16, 801-807 (2004).
73. Ronnblom L, Alm GV. Systemic lupus erythematosus and the type I interferon system. Arthritis Res. Ther. 5, 68-75 (2003).
74. Dall'era MC, Cardarelli PM, Preston BT, Witte A, Davis JC Jr. Type I interferon correlates with serological and clinical manifestations of SLE. Ann. Rheum. Dis. 64, 1692-1697 (2005).
75. Blanco P, Palucka AK, Gill M, Pascual V, Banchereau J. Induction of dendritic cell differentiation by IFN-α in systemic lupus erythematosus. Science 16, 294(5546) 1540-1543 (2001).
76. Bengtsson AA, Sturfelt G, Truedsson L, Blomberg J, Alm G, Vallin H et al. Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies. Lupus 9(9), 664-671 (2000).
77. Baechler EC, Batliwalla FM, Karypis G et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc. Natl Acad. Sci. USA 100, 2610-2615 (2003).
78. Bennett L, Palucka AK, Arce E et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J. Exp. Med. 197, 711-723 (2003).
79. Kirou KA, Lee C, George S et al. Coordinate overexpression of interferon-α-induced genes in systemic lupus erythematosus. Arthritis Rheum. 50, 3958-3967 (2004).
80. Kirou KA, Lee C, George S, Louca K, Peterson MG, Crow MK. Activation of the interferon-α pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum. 52, 1491-1503 (2005).
81. Jin O, Sun LY, Zhou KX et al. Lymphocyte apoptosis and macrophage function: correlation with disease activity in systemic lupus erythematosus. Clin. Rheumatol. 24, 107-110 (2005).
82. Utz PJ. Multiplexed assays for identification of biomarkers and surrogate markers in systemic lupus erythematosus. Lupus 13, 304-311 (2004).